Editor's note

This article was originally published on 24 April 2014 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

A landmark transaction

On 22 April 2014, GSK Biologicals announced it was acquiring the Novartis vaccines business (excluding influenza vaccines) for $5.25 billion upfront in cash with potential milestone payments of up to $1.8 billion and ongoing royalties. GSK had already demonstrated its acquisitive intent in 2013 with the purchase of Okairos AG for €250 million. This new transaction is of a different magnitude entirely, and materially reshapes the global vaccine competitive landscape.

Transaction Value
$5.25bn

GSK upfront payment for Novartis vaccines business (excluding influenza), plus up to $1.8bn in milestones

What GSK acquires

The acquired portfolio adds approximately $750 million per year in incremental vaccine revenues to GSK, primarily from the Novartis meningococcal franchise: Menveo® (MenACWY conjugate), Bexsero® (4CMenB) and Menjugate® (MenC). Travel and endemic vaccines for rabies (RabAvert/Rabipur), TBE (Encepur) and Japanese encephalitis (Ixiaro) are also included. GSK also gains pipeline programmes including MenABCWY (Phase 2) and a Group B Streptococcus maternal vaccine (Phase 2), alongside milestone-bearing royalty rights on future Bexsero® and MenB programme performance.

For Novartis: lucky to break even

Novartis paid approximately $7.5 billion for Chiron in 2007 and invested eight further years in a consistently loss-making unit. The $5.25 billion from GSK plus $1.68 billion from its diagnostics divestiture to Grifols broadly cover the initial outlay - though any profit depends on milestone payments linked to GSK's future execution of programmes Novartis spent years advancing. Some would argue the Novartis career rotation culture undermined continuity in key programmes; GSK's discrete, experienced vaccines division may avoid the same pitfall.

"It is ironic that the performance of a rival will determine whether Novartis ever makes a profit from its troubled foray into vaccines."

Manufacturing and DT bulk concentrates

An underappreciated dimension of the deal is manufacturing: Novartis had been supplying diphtheria-tetanus (DT) bulk concentrate from its Marburg plant to GSK for use in combination vaccines including Infanrix®, Pediarix®, Kinrix® and Boostrix®. The acquisition removes a key external supplier dependency for GSK's paediatric franchise, a strategic benefit beyond the headline product revenues.